These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 15337700)

  • 1. Effect of baseline or changes in adrenergic activity on clinical outcomes in the beta-blocker evaluation of survival trial.
    Bristow MR; Krause-Steinrauf H; Nuzzo R; Liang CS; Lindenfeld J; Lowes BD; Hattler B; Abraham WT; Olson L; Krueger S; Thaneemit-Chen S; Hare JM; Loeb HS; Domanski MJ; Eichhorn EJ; Zelis R; Lavori P
    Circulation; 2004 Sep; 110(11):1437-42. PubMed ID: 15337700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure.
    Liggett SB; Mialet-Perez J; Thaneemit-Chen S; Weber SA; Greene SM; Hodne D; Nelson B; Morrison J; Domanski MJ; Wagoner LE; Abraham WT; Anderson JL; Carlquist JF; Krause-Steinrauf HJ; Lazzeroni LC; Port JD; Lavori PW; Bristow MR
    Proc Natl Acad Sci U S A; 2006 Jul; 103(30):11288-93. PubMed ID: 16844790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bucindolol: a pharmacogenomic perspective on its use in chronic heart failure.
    Smart NA; Kwok N; Holland DJ; Jayasighe R; Giallauria F
    Clin Med Insights Cardiol; 2011; 5():55-66. PubMed ID: 21792345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of GRK2 in vascular smooth muscle leads to inappropriate hypertension and acute heart failure as in clinical scenario 1.
    Yano H; Onoue K; Tokinaga S; Ioka T; Ishihara S; Hashimoto Y; Nakada Y; Nakagawa H; Ueda T; Seno A; Nishida T; Watanabe M; Saito Y
    Sci Rep; 2023 May; 13(1):7707. PubMed ID: 37173348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological interventions for heart failure in people with chronic kidney disease.
    Lunney M; Ruospo M; Natale P; Quinn RR; Ronksley PE; Konstantinidis I; Palmer SC; Tonelli M; Strippoli GF; Ravani P
    Cochrane Database Syst Rev; 2020 Feb; 2(2):CD012466. PubMed ID: 32103487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bucindolol for the Maintenance of Sinus Rhythm in a Genotype-Defined HF Population: The GENETIC-AF Trial.
    Piccini JP; Abraham WT; Dufton C; Carroll IA; Healey JS; van Veldhuisen DJ; Sauer WH; Anand IS; White M; Wilton SB; Aleong R; Rienstra M; Krueger SK; Ayala-Paredes F; Khaykin Y; Merkely B; Miloradović V; Wranicz JK; Ilkhanoff L; Ziegler PD; Davis G; Emery LL; Marshall D; Kao DP; Bristow MR; Connolly SJ;
    JACC Heart Fail; 2019 Jul; 7(7):586-598. PubMed ID: 31042551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Local sympathetic denervation attenuates myocardial inflammation and improves cardiac function after myocardial infarction in mice.
    Ziegler KA; Ahles A; Wille T; Kerler J; Ramanujam D; Engelhardt S
    Cardiovasc Res; 2018 Feb; 114(2):291-299. PubMed ID: 29186414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in Left Ventricular Ejection Fraction Predict Survival and Hospitalization in Heart Failure With Reduced Ejection Fraction.
    Breathett K; Allen LA; Udelson J; Davis G; Bristow M
    Circ Heart Fail; 2016 Oct; 9(10):. PubMed ID: 27656000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The adrenergic system in pulmonary arterial hypertension: bench to bedside (2013 Grover Conference series).
    Bristow MR; Quaife RA
    Pulm Circ; 2015 Sep; 5(3):415-23. PubMed ID: 26401244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of GRK5 and ADRB1 polymorphisms influence on systolic heart failure.
    Kang S; Hong X; Ruan CW; Yu P; Yu SS; Chen M; Zhang DF; Fan HM; Liu ZM
    J Transl Med; 2015 Feb; 13():44. PubMed ID: 25638254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Race, common genetic variation, and therapeutic response disparities in heart failure.
    Taylor MR; Sun AY; Davis G; Fiuzat M; Liggett SB; Bristow MR
    JACC Heart Fail; 2014 Dec; 2(6):561-72. PubMed ID: 25443111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adrenergic signaling in heart failure: a balance of toxic and protective effects.
    Baker AJ
    Pflugers Arch; 2014 Jun; 466(6):1139-50. PubMed ID: 24623099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiac alpha1-adrenergic receptors: novel aspects of expression, signaling mechanisms, physiologic function, and clinical importance.
    O'Connell TD; Jensen BC; Baker AJ; Simpson PC
    Pharmacol Rev; 2014; 66(1):308-33. PubMed ID: 24368739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of atrial fibrillation by bucindolol is dependent on the beta₁389 Arg/Gly adrenergic receptor polymorphism.
    Aleong RG; Sauer WH; Davis G; Murphy GA; Port JD; Anand IS; Fiuzat M; O'Connor CM; Abraham WT; Liggett SB; Bristow MR
    JACC Heart Fail; 2013 Aug; 1(4):338-344. PubMed ID: 24159564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha-1-adrenergic receptors in heart failure: the adaptive arm of the cardiac response to chronic catecholamine stimulation.
    Jensen BC; OʼConnell TD; Simpson PC
    J Cardiovasc Pharmacol; 2014 Apr; 63(4):291-301. PubMed ID: 24145181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of biomarkers in predicting outcome in patients with coronary artery disease and left ventricular dysfunction: results of the biomarker substudy of the Surgical Treatment for Ischemic Heart Failure trials.
    Feldman AM; Mann DL; She L; Bristow MR; Maisel AS; McNamara DM; Walsh R; Lee DL; Wos S; Lang I; Wells G; Drazner MH; Schmedtje JF; Pauly DF; Sueta CA; Di Maio M; Kron IL; Velazquez EJ; Lee KL
    Circ Heart Fail; 2013 May; 6(3):461-72. PubMed ID: 23584092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation.
    Kao DP; Davis G; Aleong R; O'Connor CM; Fiuzat M; Carson PE; Anand IS; Plehn JF; Gottlieb SS; Silver MA; Lindenfeld J; Miller AB; White M; Murphy GA; Sauer W; Bristow MR
    Eur J Heart Fail; 2013 Mar; 15(3):324-33. PubMed ID: 23223178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combinatorial pharmacogenetic interactions of bucindolol and β1, α2C adrenergic receptor polymorphisms.
    O'Connor CM; Fiuzat M; Carson PE; Anand IS; Plehn JF; Gottlieb SS; Silver MA; Lindenfeld J; Miller AB; White M; Walsh R; Nelson P; Medway A; Davis G; Robertson AD; Port JD; Carr J; Murphy GA; Lazzeroni LC; Abraham WT; Liggett SB; Bristow MR
    PLoS One; 2012; 7(10):e44324. PubMed ID: 23071495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adrenergic-pathway gene variants influence beta-blocker-related outcomes after acute coronary syndrome in a race-specific manner.
    Cresci S; Dorn GW; Jones PG; Beitelshees AL; Li AY; Lenzini PA; Province MA; Spertus JA; Lanfear DE
    J Am Coll Cardiol; 2012 Sep; 60(10):898-907. PubMed ID: 22703928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetics in chronic heart failure: new developments and current challenges.
    Talameh JA; Lanfear DE
    Curr Heart Fail Rep; 2012 Mar; 9(1):23-32. PubMed ID: 22135185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.